Tuesday, August 21, 2018
 
 
Company News: Page (1) of 1 - 02/14/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab)
First-Ever Application to be Submitted for an MRD Positive Indication
(February 14, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords:Manufacturing,Sales,Applications,Suppliers,Manufacturing/Production,Marketing,Insurance,Shipping & Receiving,Manufacturing,Sales & Marketing,Security,Business Issues,Administration,Legal,Sales,Sales,USA,IT (Information Technology),Security,Medicine,Disease,healthcare,Cancer,Therapy,Technology,
Related Sites: DMN Newswire ,   IBN - Business ,   IBN - ProductivityApps ,   IBN - Security ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The global connected health device market is expected to reach an estimated $36.1 billion by 2023 and is forecast to grow at a CAGR of 21.1% from 2018 to 2023
  • Global Hemodialysis and Peritoneal Dialysis Market to Witness a CAGR of 5.9% during 2018-2024
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023

    Cancer
  • New ESMO Tumour DNA Scale Helps Match Patients with Cancer to Optimal Targeted Medicines
  • /R E P E A T -- Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution/
  • Singapore's first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
  • Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines